中国实用内科杂志2009，Vol.29Issue(12)：1103-1105,3.
高危骨髓增生异常综合征及急性髓系白血病治疗方案选择研究
Effects of Idarubicin and cytosine arabinoside on high-risk myelodysplastic syndromes and acute myeloid leukemia
摘要
Abstract
Objective To compare the therapeutic and side effects of idarubicin (IDA) with those of daunorubicin(DNR) in combination with cytosine arabinoside (CA) on high-risk myelodysplastic syndromes and acute myeloid leukemia (AML).Methods 29 patients(18 patients with AML,11 patients with high-risk MDS or AMI7MDS)were treated with IDA(12mg/m~2)for 3d and CA(150mg/m~2)for 7d(IA arm) and 26 patients with AML with DNR(45mg/m~2 )for 3d and CA( 150mg/m~2)for 7d( DA arm)as induction and consolidation therapies. Results (1) For AML patients, the effective rates( CR + PR) were 83. 3% in IA arm and 53. 8% in DA arm( P = 0.042); For patients with higher white blood cell count (≥30×10~9/L) ,the effective rates were 81. 3% in IA arm and 25% in DA arm (P =0.009) ;For elder patients ( ≥ 65y) , the effective rates were 66. 7% in IA arm and 0% in DA arm (P = 0.045);(2) Treatment with IA could also offer significant advantages to high-risk MDS or AML/MDS patients with higher effective rates(83.3%) which was similar to that of AML patients by IA(72.7%). Age and Hyperleukocytosis(≥30 ×10~9/L)could not affect the effective rates in IA arm;(3) The main toxicity of IA was longer myelosuppression with lower WBC below 4 ×10~9/L which was averagely up to (24.1 7.7)d. Hemorrhage, nausea, vomit, hepatic and renal dysfunction and heart toxicity occurred unfrequently. Con-clusion IA was superior to DA as induction and consolidation therapies for AML and also effective for high-risk MDS or MDS-develeped AML. Age and hyperleukocytosis could not affect the effects of IA. IA can be the first therapy choice for the patients with AML and high-risk MDS.关键词
IA方案/急性髓系白血病/高危骨髓增生异常综合征Key words
idarubicin/high-risk myelodysplastic syndromes /a-cute myeloid leukemia分类
医药卫生引用本文复制引用
刘惠,刘鸿,吴玉红,王化泉,邢莉民,关晶,王珺 ,李丽娟,付蓉,邵宗鸿,阮二宝,王晓明,王国锦,梁勇,瞿文,宋嘉..高危骨髓增生异常综合征及急性髓系白血病治疗方案选择研究[J].中国实用内科杂志,2009,29(12):1103-1105,3.基金项目
"十-五"国家科技支撑计划(2008BAl61B02) （2008BAl61B02）
天津市科技支撑计划,重大疾病防治专项基金(07ZCGYSF00600) （07ZCGYSF00600）
天津市应用基础及前沿技术研究计划(09JCYBJCl1200) （09JCYBJCl1200）
